Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting April 29, 2025
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company January 16, 2025
Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform December 9, 2024
Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia September 30, 2024
